Ticker brief
ARGX ARGENX SE - ADR
Consumer, Non-cyclical · Biotechnology
last close
$873.71
1 day
-0.2%
14 days
+5.9%
mkt cap
·
signals 14d
29
authors 14d
16
crowd 14d
-0.8σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-16 · now +0.45 (−1 bearish … +1 bullish)
Who spoke16
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 5 | +0.20 |
| @UTEX_io | C | +0.04 | 3 | -0.22 |
| @scetrader | C | -2.00 | 3 | -0.48 |
| @SDCtrader | C | +0.15 | 2 | -0.35 |
| @fwpharma | B | -1.91 | 2 | -0.05 |
| @Briefingcom | B | -2.26 | 2 | -0.48 |
| @BiopharmIQ | B | · | 2 | -0.47 |
| @BiotechCH | B | +1.42 | 2 | +0.45 |
| @CrweWorld | C | · | 1 | +0.45 |
| @Newsquawk | B | · | 1 | -0.80 |
| @BPharmCatalyst | C | · | 1 | -0.55 |
| @OpenOutcrier | C | · | 1 | -0.70 |
| @AnthonySandford | C | · | 1 | +0.00 |
| @FiercePharma | B | +0.46 | 1 | -0.45 |
| @ClassicRoy | C | -1.10 | 1 | +0.00 |
| @PersimmonTI | A | +0.79 | 1 | +0.00 |
Recent signals29of 29 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BiotechCH | +0.40 | Highlights encouraging cross-indication data and upcoming catalysts for three biotech firms. | +6.7% | tweet ↗ |
| 2026-10-16 | @BiotechCH | +0.50 | TRAX and ARGX reported positive celiac-disease trial data ahead of a November meeting. | +6.7% | tweet ↗ |
| 2026-10-12 | @scetrader | -0.40 | Deutsche Bank cut Argenx's target to €850 from €950 while retaining Hold. | +7.6% | tweet ↗ |
| 2026-10-11 | @PersimmonTI | +0.00 | Reports the scheduled October 12 Phase 1b celiac top-line data release and webcast. | +5.9% | tweet ↗ |
| 2026-10-09 | @BiopharmIQ | -0.45 | Summarizes large biotech moves tied to a buyout and trial outcomes, then flags upcoming studies. | +5.9% | tweet ↗ |
| 2026-10-09 | @OzmosiHealth | +0.00 | Argenx presented Phase 2 celiac-disease results for FB-102 on Oct. 8. | +5.9% | tweet ↗ |
| 2026-10-08 | @ClassicRoy | +0.00 | Lists instruments for a 1 p.m. trading lineup without providing direction. | +6.7% | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | -0.50 | Summarizes large biotech moves and lists upcoming Phase 2 and Phase 3 catalysts. | +6.7% | tweet ↗ |
| 2026-10-08 | @FiercePharma | -0.45 | Argenx discontinued a Vyvgart Hytrulo trial in Sjögren's disease. | +6.7% | tweet ↗ |
| 2026-10-08 | @AnthonySandford | +0.00 | Lists the largest $10M-plus dark-pool prints and cautions they are levels, not automatic directions. | +6.7% | tweet ↗ |
| 2026-10-08 | @OzmosiHealth | +0.50 | Company reported positive topline Phase 2 celiac-disease results. | +6.7% | tweet ↗ |
| 2026-10-08 | @OzmosiHealth | +0.50 | Company reported positive topline Phase 2 celiac-disease results. | +6.7% | tweet ↗ |
| 2026-10-08 | @OzmosiHealth | +0.00 | Company announced an unspecified update on its Phase 3 UNITY study. | +6.7% | tweet ↗ |
| 2026-10-08 | @OzmosiHealth | +0.00 | Company announced an unspecified update on its Phase 3 UNITY study. | +6.7% | tweet ↗ |
| 2026-10-08 | @UTEX_io | -0.65 | Argenx halted a phase 3 study after futility analysis indicated it was unlikely to succeed. | +6.7% | tweet ↗ |
| 2026-10-08 | @OpenOutcrier | -0.70 | argenx halted a Phase 3 Sjögren's trial after a futility finding. | +6.7% | tweet ↗ |
| 2026-10-08 | @Briefingcom | -0.55 | Phase 3 UNITY trial was discontinued after a futility review. | +6.7% | tweet ↗ |
| 2026-10-08 | @BPharmCatalyst | -0.55 | ARGX will stop a Phase 3 Sjögren's trial for futility, partly offset by favorable Phase 2 celiac data. | +6.7% | tweet ↗ |
| 2026-10-08 | @Briefingcom | -0.40 | Lists the largest premarket gaps; output retains the first six tickers under the schema cap. | +6.7% | tweet ↗ |
| 2026-10-08 | @Newsquawk | -0.80 | Premarket roundup quantifies major movers and company-specific catalysts; six most salient names retained. | +6.7% | tweet ↗ |
| 2026-10-08 | @CrweWorld | +0.45 | Reports positive topline Phase 2 study results for FB102 in celiac disease. | +6.7% | tweet ↗ |
| 2026-10-08 | @fwpharma | +0.40 | argenX will advance its CD122 inhibitor into Phase III for coeliac disease. | +6.7% | tweet ↗ |
| 2026-10-08 | @fwpharma | -0.50 | argenx ended a late-stage Vyvgart study in Sjögren’s disease for futility. | +6.7% | tweet ↗ |
| 2026-10-08 | @SDCtrader | -0.70 | Indicators imply ARGX has not set a monthly bottom and may reach the demand zone. | +6.7% | tweet ↗ |
| 2026-10-08 | @scetrader | -0.45 | Says positive FB102 data do not offset a failed Sjögren study for Argenx. | +6.7% | tweet ↗ |
| 2026-10-08 | @scetrader | -0.60 | Reports a difficult European open with Argenx falling sharply. | +6.7% | tweet ↗ |
| 2026-10-07 | @UTEX_io | +0.50 | Phase 2 FB102 trial met its primary endpoint and is planned to advance to Phase 3. | -5.9% | tweet ↗ |
| 2026-10-07 | @UTEX_io | -0.50 | ARGX is discontinuing a Phase 3 study after a futility recommendation. | -5.9% | tweet ↗ |
| 2026-10-03 | @SDCtrader | +0.00 | Promotes long-term chart views and setups but provides no ticker-specific conclusions or levels in the text. | -4.9% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.